1.Anti-infectious agents 1.1.Chemotheurapeutics 1.1.1.Sulfonamides 1.1.2.Diamino pyrimidine derivatives 1.2.Antibiotics 1.2.1.Penicillins 1.2.2.Cephalosporins 1.2.3.Quinolones 1.2.4.Macrolides 1.2.5.Florfenicol and related compounds 1.2.6.Tetracyclines 1.2.7.Naphtalene-ringed ansamycin 1.2.8.Pleuromutilines 1.2.9.Lincosamides 1.2.10.Aminoglycosides 1.2.11.Other antibiotics 1.2.12.Polypeptides 1.2.13.Beta-lactamase inhibitors 1.2.14.Polymyxins 2.Antiparasitic agents 2.1.Agents acting against endoparasites 2.1.1.Salicylanilides 2.1.2.Tatra-hydro-imidazoles (imidazolthiazoles) 2.1.3.Benzimidazoles and pro-benzimidazoles 2.1.4.Phenol derivatives including salicylanides 2.1.5.Benzenesulphonamides 2.1.6.Piperazine derivatives 2.1.7.Tetrahydropyrimides 2.2.Agents acting against ectoparasites 2.2.1.Organophosphates 2.2.2.Formamidines 2.2.3.Pyrethroids 2.2.4.Acyl urea derivatives 2.2.5.Pyrimidines derivatives 2.2.6.Triazine derivatives 2.3.Agents acting against endo- and ectoparasites 2.3.1.Avermectins 2.4.Agents acting against protozoa 2.4.1.Triazinetrione derivative 2.4.2.Quinazolone derivatives 2.4.3.Carbanilides 3.Agents acting on the nervous system 3.1.Agents acting on the central nervous system 3.1.1.Butyrophenone tranquillisers 3.2.Agents acting on the autonomic nervous system 3.2.1.Anti-adrenergics 3.2.2.β2 sympathomimetic agents 4.Anti-inflammatory agents 4.1.Nonsteroidal anti-inflammatory agents 4.1.1.Arylpropionic acid derivative 4.1.2.Fenamate group derivatives 4.1.3.Enolic acid derivates 4.1.4.Oxican derivatives 4.1.5.Pyrazolone derivatives 4.1.6.Phenyl acetic acid derivatives 5.Corticoides 5.1.Glucocorticoides 6.Agents acting on the reproductive system 6.1.Progestogens 1.Inorganic chemicals 2.Organic compounds 3.Substances generally recognised as safe 4.Substances used in homeopathic veterinary medicinal products 5.Substances used as food additives in foodstuffs for human consumption...6.Substances of vegetable origin 7.Anti-infectious agents 1.Anti-infectious agents 1.1.Chemotheurapeutics 1.1.2.Benzenesulphonamides 1.2.Antibiotics 1.2.1.Beta-lactamase inhibitors 1.2.2.Macrolides 1.2.4.Cephalosporins 1.2.5.Aminoglycosides 1.2.6.Quinolones 1.2.9.Polymyxins 1.2.10.Penicillins 1.2.11.Florfenicol and related compounds 1.2.12.Polypeptides 1.2.13.Lincosamides 1.2.14.Pleuromutilines 2.Antiparasitic agents 2.1.Agents acting against endoparasites 2.1.1.Phenol derivatives including salicylanides 2.1.2.Benzimidazoles and pro-benzimidazoles 2.1.3.Tetrahydropyrimides 2.1.5.Piperazine derivatives 2.1.6.Salicylanilides 2.2.Agents acting against ectoparasites 2.2.1.Formamidines 2.2.2.Iminophenyl thiazolidine derivative 2.2.3.Pyretrin and pyrethroids 2.2.4.Organophosphates 2.2.5.Acyl urea derivates 2.2.6.Pyrimidines derivatives 2.2.7.Triazine derivatives 2.3.Agents acting against endo- and ectoparasites 2.3.1.Avermectins 2.4.Agents acting against protozoa 2.4.1.Carbanilides 2.4.2.Quinazolone derivatives 2.4.3.Triazinetrione derivatives 2.4.4.Other anti-protozoal agents 3.Agents acting on the nervous system 3.2.Agents acting on the autonomic nervous system 3.2.1.β 2 sympathomimetic agents 3.2.2.Anti-adrenergics 5.Anti-inflammatory agents 5.1.Nonsteroidal anti-inflammatory agents 5.1.1.Arylpropionic acid derivative 5.1.2.Enolic acid derivates 5.1.3.Pyrazolone derivatives 6.Agents acting on the reproductive system 6.1.Progestogens 7.Corticoids 7.1.Glucocorticoids Administrative particulars 1Name or corporate name and permanent address of the applicant....2Name of the veterinary medicinal product. 3Qualitative and quantitative composition in terms of active principles, with...4Manufacturing authorization, if any. 5Marketing authorization, if any. 6Summary of the characteristics of the veterinary medicinal product(s) prepared...A.Safety documentation A.0.Expert report A.1.Precise identification of the substance concerned by the application 1.1International non-proprietary name (INN). 1.2International Union of Pure and Applied Chemistry (IUPAC) name. 1.3Chemical Abstract Service (CAS) name. 1.4Classification: 1.5Synonyms and abbreviations. 1.6Structural formula. 1.7Molecular formula. 1.8Molecular weight. 1.9Degree of impurity. 1.10Qualitative and quantitative composition of impurities. 1.11Description of physical properties: A.2.Relevant pharmacological studies 2.1Pharmacodynamics. 2.2Pharmacokinetics. A.3.Toxicological studies 3.1Single dose toxicity. 3.2Repeated dose toxicity. 3.3Tolerance in the target species of animal. 3.4Reproductive toxicity, including teratogenicity. 3.4.1Study of the effects on reproduction. 3.4.2Embryotoxicity/fetotoxicity, including teratogenicity. 3.5Mutagenicity. 3.6Carcinogenicity. A.4.Studies of other effects 4.1Immunotoxicity. 4.2Microbiological properties of residues. 4.2.1On the human gut flora; 4.2.2On the organisms and microorganisms used for industrial food-processing. 4.3Observations in humans. B.Residue documentation B.0Expert report B.1.Precise identification of the substance concerned by the application B.2.Residue studies 2.1Pharmacokinetics 2.2Depletion of residues. 2.3Elaboration of maximum residue limits (MRLS). B3.Routine analytical method for the detection of residues 3.1Description of the method. 3.2Validation of the method. 3.2.1specificity; 3.2.2accuracy, including sensitivity; 3.2.3precision; 3.2.4limit of detection; 3.2.5limit of quantitation; 3.2.6practicability and applicability under normal laboratory conditions; 3.2.7susceptibility to interference.

Council Regulation (EEC) No 2377/90

of 26 June 1990

laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (repealed)

THE COUNCIL OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Economic Community, and in particular Article 43 thereof,

Having regard to the proposal from the Commission1,

Having regard to the opinion of the European Parliament2,

Having regard to the opinion of the Economic and Social Committee3,

Whereas the use of veterinary medicinal products in food-producing animals may result in the presence of residues of foodstuffs obtained from treated animals;

Whereas as a result of scientific and technical progress it is possible to detect the presence of residues of veterinary medicines in foodstuffs at ever lower levels; whereas it is therefore necessary to establish maximum residue limits for pharmacologically active substances which are used in veterinary medicinal products in respect of all the various foodstuffs of animal origin, including meat, fish, milk, eggs and honey;

Whereas in order to protect public health, maximum residue limits must be established in accordance with generally recognized principles of safety assessment, taking into account any other scientific assessment of the safety of the substances concerned which may have been undertaken by international organizations, in particular the Codex Alimentarius or, where such substances are used for other purposes, by other scientific committees established within the Community;

Whereas the use of veterinary medicinal products plays an important part in agricultural production; whereas the establishment of maximum residue levels will facilitate the marketing of foodstuffs of animal origin;

Whereas the establishment of different maximum residue levels by Member States may hinder the free movement of foodstuffs and of veterinary medicinal products themselves;

Whereas it is therefore necessary to lay down a procedure for the establishment of maximum residue levels of veterinary medicinal products by the Community, following a single scientific assessment of the highest possible quality;

Whereas the need for the establishment of maximum residue levels throughout the Community is recognized in the Community rules relating to trade in foodstuffs of animal origin;

Whereas provisions must be adopted with a view to the systematic establishment of maximum residue levels for new substances capable of pharmacological action intended for administration to food-producing animals;

Whereas arrangements must also be made for the establishment of maximum residue levels for substances which are currently used in veterinary medicines administered to food-producing animals; whereas, however, in view of the complexity of this matter and the large number of substances involved, long transitional arrangements are required;

Whereas, after scientific assessment by the Committee for Veterinary Medicinal Products, maximum residue levels must be adopted by a rapid procedure which ensures close cooperation between the Commission and the Member States through the Committee set up under Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products4, as last amended by Directive 87/20/EEC5; whereas an urgent procedure is also required to ensure the swift review of any tolerance which might prove insufficient to protect public health;

Whereas medicinally induced immunological responses are usually indistinguishable from those which arise naturally, and do not affect consumers of food of animal origin;

Whereas the information necessary to assess the safety of residues should be presented in accordance with the principles laid down by Directive 81/852/EEC,

HAS ADOPTED THIS REGULATION: